MX357770B - Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. - Google Patents
Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.Info
- Publication number
- MX357770B MX357770B MX2013002722A MX2013002722A MX357770B MX 357770 B MX357770 B MX 357770B MX 2013002722 A MX2013002722 A MX 2013002722A MX 2013002722 A MX2013002722 A MX 2013002722A MX 357770 B MX357770 B MX 357770B
- Authority
- MX
- Mexico
- Prior art keywords
- sdf
- disorder
- disease
- nucleic acids
- cancer treatment
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 10
- 201000010099 disease Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 5
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 abstract 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10009397 | 2010-09-09 | ||
| PCT/EP2011/004554 WO2012031773A1 (en) | 2010-09-09 | 2011-09-09 | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013002722A MX2013002722A (es) | 2013-06-28 |
| MX357770B true MX357770B (es) | 2018-07-24 |
Family
ID=44653255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013002722A MX357770B (es) | 2010-09-09 | 2011-09-09 | Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20130310442A1 (OSRAM) |
| EP (1) | EP2613789B1 (OSRAM) |
| JP (1) | JP6243736B2 (OSRAM) |
| KR (1) | KR101937939B1 (OSRAM) |
| CN (1) | CN103108641B (OSRAM) |
| AU (1) | AU2011300818B2 (OSRAM) |
| BR (1) | BR112013005664B8 (OSRAM) |
| CA (1) | CA2810950C (OSRAM) |
| DK (1) | DK2613789T3 (OSRAM) |
| ES (1) | ES2678497T3 (OSRAM) |
| MX (1) | MX357770B (OSRAM) |
| RU (1) | RU2679495C2 (OSRAM) |
| SG (2) | SG188220A1 (OSRAM) |
| WO (1) | WO2012031773A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2613789B1 (en) * | 2010-09-09 | 2018-04-18 | Noxxon Pharma AG | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
| EP3443095A1 (en) * | 2016-04-15 | 2019-02-20 | Noxxon Pharma AG | Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors |
| EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | RaQualia Pharma Inc. | Method for selecting cancer patient for which combination therapy of retinoid and cancer treatment agent will be effective, and combined drug of retinoid and cancer treatment agent |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) * | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| ATE333896T1 (de) | 1998-03-24 | 2006-08-15 | Chugai Pharmaceutical Co Ltd | Vaskularisierungsinhibitoren |
| JP4786793B2 (ja) * | 1998-03-30 | 2011-10-05 | ノースウエスト バイオセラピューティクス，インコーポレイティド | 腫瘍形成におけるｃｘｃｒ−４遺伝子の役割に基く治療的および診断的応用 |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| EP1297121B1 (en) * | 2000-06-26 | 2005-05-04 | Wellstat Biologics Corporation | Purging of cells using viruses |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| US20060019917A1 (en) * | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
| US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
| KR100598309B1 (ko) | 2001-06-07 | 2006-07-10 | 케모센트릭스, 인크. | 세포 이동성 검사 |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| DK1438321T5 (da) | 2001-10-26 | 2011-02-21 | Noxxon Pharma Ag | Modificeret L-nukleinsyre |
| WO2003070823A2 (en) | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| JP2006524242A (ja) * | 2003-03-27 | 2006-10-26 | エモリー ユニバーシティー | Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法 |
| MXPA05011022A (es) | 2003-04-13 | 2006-04-27 | Enzon Pharmaceuticals Inc | Profarmacos oligonucleotidos polimericos. |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| HUE045882T2 (hu) | 2004-03-23 | 2020-01-28 | Ascendis Pharma Gmbh | Polimer prodrug önmagát lehasító linkerrel |
| JP5107716B2 (ja) | 2004-11-05 | 2012-12-26 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 分子治療用生分解性リンカー |
| EP1883651A1 (en) * | 2005-05-26 | 2008-02-06 | Rappaport Family Institute For Research in the Medical Sciences | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
| JP2009504788A (ja) * | 2005-08-19 | 2009-02-05 | ジェンザイム・コーポレーション | 化学療法の強化方法 |
| MX2009000656A (es) * | 2006-07-18 | 2009-03-25 | Noxxon Pharma Ag | Acidos nucleicos que se fijan a sdf-i. |
| US8496931B2 (en) * | 2006-08-11 | 2013-07-30 | Medarex, Inc. | Monoclonal antibodies against stromal derived factor-1 (SDF-1) |
| CA2662978A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| CA2672944A1 (en) * | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders |
| BRPI0815094B8 (pt) | 2007-08-06 | 2023-04-18 | Noxxon Pharma Ag | Uso de uma molécula de ácido l-nucleico ligada a sdf-1 |
| EP2613789B1 (en) * | 2010-09-09 | 2018-04-18 | Noxxon Pharma AG | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
-
2011
- 2011-09-09 EP EP11757776.7A patent/EP2613789B1/en active Active
- 2011-09-09 KR KR1020137006584A patent/KR101937939B1/ko active Active
- 2011-09-09 BR BR112013005664A patent/BR112013005664B8/pt active IP Right Grant
- 2011-09-09 ES ES11757776.7T patent/ES2678497T3/es active Active
- 2011-09-09 US US13/821,669 patent/US20130310442A1/en not_active Abandoned
- 2011-09-09 CA CA2810950A patent/CA2810950C/en active Active
- 2011-09-09 AU AU2011300818A patent/AU2011300818B2/en active Active
- 2011-09-09 DK DK11757776.7T patent/DK2613789T3/en active
- 2011-09-09 CN CN201180043233.4A patent/CN103108641B/zh active Active
- 2011-09-09 JP JP2013527497A patent/JP6243736B2/ja active Active
- 2011-09-09 RU RU2013115739A patent/RU2679495C2/ru active
- 2011-09-09 SG SG2013011150A patent/SG188220A1/en unknown
- 2011-09-09 MX MX2013002722A patent/MX357770B/es active IP Right Grant
- 2011-09-09 SG SG10201506725QA patent/SG10201506725QA/en unknown
- 2011-09-09 WO PCT/EP2011/004554 patent/WO2012031773A1/en not_active Ceased
-
2015
- 2015-11-20 US US14/947,173 patent/US9387221B2/en active Active
-
2016
- 2016-07-03 US US15/201,477 patent/US10093934B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201506725QA (en) | 2015-10-29 |
| DK2613789T3 (en) | 2018-07-23 |
| AU2011300818A1 (en) | 2013-03-07 |
| KR101937939B1 (ko) | 2019-01-11 |
| RU2679495C2 (ru) | 2019-02-11 |
| ES2678497T3 (es) | 2018-08-13 |
| MX2013002722A (es) | 2013-06-28 |
| CN103108641A (zh) | 2013-05-15 |
| BR112013005664B1 (pt) | 2021-11-03 |
| US20130310442A1 (en) | 2013-11-21 |
| WO2012031773A1 (en) | 2012-03-15 |
| SG188220A1 (en) | 2013-04-30 |
| KR20130114094A (ko) | 2013-10-16 |
| JP2013540725A (ja) | 2013-11-07 |
| EP2613789B1 (en) | 2018-04-18 |
| JP6243736B2 (ja) | 2017-12-06 |
| US20160095875A1 (en) | 2016-04-07 |
| CN103108641B (zh) | 2016-01-13 |
| CA2810950A1 (en) | 2012-03-15 |
| RU2013115739A (ru) | 2014-10-20 |
| BR112013005664B8 (pt) | 2023-04-25 |
| US10093934B2 (en) | 2018-10-09 |
| CA2810950C (en) | 2023-02-14 |
| EP2613789A1 (en) | 2013-07-17 |
| BR112013005664A2 (pt) | 2020-08-04 |
| AU2011300818B2 (en) | 2015-11-12 |
| HK1184699A1 (zh) | 2014-01-30 |
| US20160355821A1 (en) | 2016-12-08 |
| US9387221B2 (en) | 2016-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
| WO2012062925A3 (en) | Compounds and methods for treating pain | |
| PH12015500832A1 (en) | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| IN2015DN00450A (OSRAM) | ||
| JO3776B1 (ar) | التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf | |
| MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
| MX2015002371A (es) | Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos. | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| WO2012038504A3 (en) | Breast cancer therapeutics | |
| EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
| WO2014111458A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| EA201491726A1 (ru) | Конъюгаты бороновых кислот олигонуклеотидных аналогов | |
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| BR112013029182A2 (pt) | método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas | |
| EP3581653A3 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| WO2010108657A3 (en) | C5a binding nucleic acids and the use thereof | |
| MX357770B (es) | Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. | |
| MX2013003168A (es) | Anticuerpo contra ephrin b2 y su uso. | |
| WO2012119989A3 (en) | Antibodies against cadmi for the diagnosis and treatment of cancer | |
| GB201004761D0 (en) | Method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |